NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company
NanoViricides (NYSE:NNVC) addresses recent stock price decline, emphasizing its immunity to tariffs and government spending cuts. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral showing promise against multiple viruses including measles, RSV, MPox, and influenza.
The company is preparing for a Phase II clinical trial of NV-387 for MPox treatment in Central Africa. NV-387's unique mechanism mimics host-side signatures that viruses target, potentially effective against 90% of human pathogenic viruses. The company also highlights NV-HHV-1, their herpesvirus antiviral candidate, and NV-HIV-1 for HIV/AIDS treatment.
Management believes the recent stock decline alongside market sell-off is misguided, positioning NNVC as a potential hedge against market turmoil due to its strong long-term prospects in antiviral drug development.
NanoViricides (NYSE:NNVC) affronta il recente calo del prezzo delle azioni, sottolineando la sua immunità ai dazi e ai tagli alla spesa pubblica. Il principale candidato farmaco dell'azienda, NV-387, è un antivirale ad ampio spettro che mostra promesse contro diversi virus, tra cui morbillo, RSV, MPox e influenza.
L'azienda si sta preparando per un trial clinico di Fase II di NV-387 per il trattamento di MPox in Africa Centrale. Il meccanismo unico di NV-387 imita le firme del lato ospite che i virus prendono di mira, risultando potenzialmente efficace contro il 90% dei virus patogeni umani. L'azienda evidenzia anche NV-HHV-1, il loro candidato antivirale per l'herpesvirus, e NV-HIV-1 per il trattamento dell'HIV/AIDS.
La direzione ritiene che il recente calo delle azioni, insieme alla svendita del mercato, sia errato, posizionando NNVC come una potenziale protezione contro le turbolenze di mercato grazie alle sue solide prospettive a lungo termine nello sviluppo di farmaci antivirali.
NanoViricides (NYSE:NNVC) aborda la reciente caída en el precio de sus acciones, enfatizando su inmunidad a los aranceles y recortes en el gasto gubernamental. El principal candidato a fármaco de la compañía, NV-387, es un antiviral de amplio espectro que muestra promesas contra múltiples virus, incluyendo sarampión, RSV, MPox e influenza.
La compañía se está preparando para un ensayo clínico de Fase II de NV-387 para el tratamiento de MPox en África Central. El mecanismo único de NV-387 imita las firmas del lado del huésped que los virus atacan, siendo potencialmente efectivo contra el 90% de los virus patógenos humanos. La compañía también destaca NV-HHV-1, su candidato antiviral para el herpesvirus, y NV-HIV-1 para el tratamiento del VIH/SIDA.
La dirección cree que la reciente caída de las acciones, junto con la venta masiva del mercado, es errónea, posicionando a NNVC como una posible cobertura contra la turbulencia del mercado debido a sus sólidas perspectivas a largo plazo en el desarrollo de fármacos antivirales.
나노바이러스(NYSE:NNVC)는 최근 주가 하락에 대응하며, 관세와 정부 지출 삭감에 대한 면역성을 강조합니다. 회사의 주요 약물 후보인 NV-387은 홍역, RSV, MPox 및 인플루엔자를 포함한 여러 바이러스에 대한 가능성을 보이는 광범위 항바이러스제입니다.
회사는 중앙 아프리카에서 MPox 치료를 위한 2상 임상 시험을 준비하고 있습니다. NV-387의 독특한 메커니즘은 바이러스가 목표로 하는 숙주 측 서명을 모방하여 인체 병원성 바이러스의 90%에 대해 효과적일 수 있습니다. 회사는 또한 헤르페스 바이러스 항바이러스 후보인 NV-HHV-1과 HIV/AIDS 치료를 위한 NV-HIV-1을 강조합니다.
경영진은 최근 주가 하락과 시장 매도가 잘못된 것이라고 믿으며, NNVC를 항바이러스 약물 개발에서의 강력한 장기 전망 덕분에 시장 혼란에 대한 잠재적 헤지로 자리매김하고 있습니다.
NanoViricides (NYSE:NNVC) aborde la récente baisse du prix de ses actions, en soulignant son immunité aux droits de douane et aux coupes budgétaires gouvernementales. Le principal candidat médicament de l'entreprise, NV-387, est un antiviral à large spectre montrant des promesses contre plusieurs virus, y compris la rougeole, le RSV, le MPox et la grippe.
L'entreprise se prépare à un essai clinique de Phase II de NV-387 pour le traitement du MPox en Afrique centrale. Le mécanisme unique de NV-387 imite les signatures du côté hôte que les virus ciblent, pouvant potentiellement être efficace contre 90 % des virus pathogènes humains. L'entreprise met également en avant NV-HHV-1, leur candidat antiviral contre le virus de l'herpès, et NV-HIV-1 pour le traitement du VIH/SIDA.
La direction considère que la récente baisse des actions, accompagnée d'une vente massive sur le marché, est malavisée, positionnant NNVC comme une protection potentielle contre les turbulences du marché grâce à ses solides perspectives à long terme dans le développement de médicaments antiviraux.
NanoViricides (NYSE:NNVC) geht auf den jüngsten Rückgang des Aktienkurses ein und betont seine Immunität gegenüber Zöllen und Kürzungen der Staatsausgaben. Der Hauptkandidat des Unternehmens, NV-387, ist ein Breitbandantivirus, das vielversprechend gegen mehrere Viren wie Masern, RSV, MPox und Influenza wirkt.
Das Unternehmen bereitet sich auf eine Phase-II-Studie von NV-387 zur Behandlung von MPox in Zentralafrika vor. Der einzigartige Mechanismus von NV-387 ahmt die Wirtsunterschriften nach, die Viren anvisieren, und könnte gegen 90 % der menschlichen pathogenen Viren wirksam sein. Das Unternehmen hebt auch NV-HHV-1, ihren antiviralen Kandidaten gegen Herpesviren, und NV-HIV-1 zur Behandlung von HIV/AIDS hervor.
Die Geschäftsführung ist der Meinung, dass der jüngste Rückgang der Aktien zusammen mit dem Marktverkauf fehlgeleitet ist und positioniert NNVC als potenziellen Schutz gegen Marktturbulenzen aufgrund seiner starken langfristigen Perspektiven in der Entwicklung antiviraler Medikamente.
- NV-387 showed superior effectiveness against Influenza A compared to approved drugs Tamiflu and Xofluza in animal models
- Company preparing for Phase II clinical trials for MPox treatment where no current treatment exists
- Technology platform effective against multiple virus types, including measles, RSV, and COVID
- Broad intellectual property portfolio with exclusive licenses for multiple viral treatments
- No exact timeline provided for IND filing
- Heavy dependence on external collaborators and consultants for drug development
- No products currently approved or generating revenue
- Drug development path requires substantial capital and lengthy timelines
SHELTON, CT / ACCESS Newswire / March 11, 2025 / NanoViricides, Inc. (the "Company")(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its business is not affected by the tariff policies of the US government or corresponding retaliatory policies of other governments, nor is it affected by the spending cuts being implemented by the current White House administration.
Therefore, the Company believes that smart financial strategists would view the longer term strong prospects of the Company (explained below) as supporting the case of NNVC as an effective hedge against the current general stock market turmoil.
Additionally, the Company reports that it does not develop vaccines. On the contrary, the Company is developing antiviral treatments, that are for helping patients infected by viruses.
"We believe that the policies of the current Secretary of HHS, Mr. Robert F. Kennedy, would lead to focusing more strongly on development of broad-spectrum antiviral treatments such as our clinical-stage as well as earlier-stage antiviral pipeline drug products rather than the previous vaccine-focused strategy," said Anil R. Diwan, PhD, President and Executive Chairman of the Company.
The Company has recently suggested that its revolutionary broad-spectrum antiviral drug NV-387 could have strong potential for the treatment of measles.
NV-387 was found to cure a lethal RSV infection in an animal model. Both Measles virus and RSV belong to the same family of viruses called paramyxoviruses. This family of viruses use heparan sulfated proteoglycans as their first stop, congregating next to cells, before gaining entry into cells.
There is no treatment available for measles; the lack of treatment is fueling the spread of this highly contagious disease.
Only a treatment for measles can effectively limit transmission of the virus and spread of the contagion, the Company believes.
It is illogical and unscientific to believe that vaccination, which is being widely promoted, would have any immediate effect for controlling the current outbreak. This is because the vaccinated person will only become protected several weeks after receiving the vaccine dose. Additionally, immune-compromised subjects cannot be vaccinated.
Although measles is spreading primarily in unvaccinated children, a small proportion of vaccinated persons is also being infected, and could suggest a drift in the virus towards partial vaccine escape. The rapid spread of measles in West Texas is bleeding into nearby areas due to travel. Several other states have reported independently initiated measles cases as well. So far there were two deaths with measles.
NV-387 mimics host-side signature required by viruses that does not change even as the viruses keep changing. In particular, NV-387 mimics heparan-sulfate-like structures to which over
The Company is currently working on a clinical trial application for enabling a Phase II human clinical trial to assess effectiveness of NV-387 for the treatment of MPox infection in the Central African region. An MPox epidemic has been raging in this region since June, 2024.
NV-387 could readily be approved for the treatment of MPox if successful in the Phase II clinical trial. There is no treatment for MPox at present.
NV-387 was found to be highly effective against Influenza A lethal infection in an animal model, significantly surpassing the effectiveness of known approved drugs including Tamiflu® and Xofluza®. These data indicate that NV-387 should be readily approvable for influenza virus infections. NV-387 is expected to be effective against bird flu viruses H5N1, H5Nx etc. as well.
NV-387 was found to be highly effective in lethal virus infection animal models for COVID. As of today's 5-year anniversary of WHO declaration of the global COVID-19 pandemic, COVID has continued in the global population as endemic infections that produce sporadic waves. The only drug available remains Paxlovid® that was found to have no benefits compared to placebo in otherwise healthy adults that became sick with SARS-CoV-2 infection in clinical trials.
"We believe NV-387 has a bright future," said Dr. Diwan, adding, "And we are strategizing to bring this future closer to reality every day."
The Company has also developed a herpesvirus family antiviral, NV-HHV-1, that has indications against HSV-1, HSV-2, as well as VZV (shingles). NV-HHV-1 has gone through IND-enabling studies as a skin cream formulation for topical treatment of shingles rash, HSV-1 cold sores, and HSV-2 ulcers. The Company is developing a systemic drug based on NV-HHV-1 for oral treatment of herpesvirus infections as well. NV-HHV-1 awaits behind NV-387 in the pipeline for clinical development.
Additionally, the Company has also developed a drug against HIV/AIDS, namely NV-HIV-1. The Company believes NV-HHV-1 in combination with some of the existing drugs could lead to achieving cures of HIV infection.
"With all of these developments in progress, we are not exposed to current macroeconomic factors such as wars, tariffs, export taxes, or spending cuts," said Dr. Diwan, explaining, "In fact, we believe that smart financial strategists would be recommending NNVC with its strong long term potential to act as a hedge against the current turmoil in the stock markets."
"Therefore, we believe that the recent decline in the Company's stock price concomitant with the general market sell-off is misguided and smart investors are expected to avail this dip opportunity," said Dr. Diwan.
ABOUT NANOVIRICIDES
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides, Inc.
View the original press release on ACCESS Newswire
FAQ
What is NanoViricides' (NNVC) lead drug candidate and how does it work?
What clinical trials is NNVC currently pursuing for NV-387?
How many antiviral candidates does NNVC have in development as of March 2025?
Why does NNVC claim its stock price decline is misguided in March 2025?
